- Details
- Isla Garraway discusses her team's study that explores how neighborhood deprivation, race, and ethnicity impact prostate cancer outcomes across California healthcare systems. Dr. Garraway highlights the significant disparities in prostate cancer incidence and outcomes, particularly among Black men and those in deprived neighborhoods. The study compares outcomes between veterans treated in the VA s...
|
- Details
- Alicia Morgans speaks with Neha Vapiwala about advancements in radiotherapy for high-risk and locally advanced prostate cancer. Dr. Vapiwala highlights the importance of dose escalation in improving survival and explains the benefits of moderate and ultra-hypofractionation, including the use of stereotactic body radiotherapy (SBRT). She emphasizes that while SBRT can safely deliver higher doses of...
|
- Details
- Zach Klaassen interviews Ahmed Ghazi about his work in robotic simulation. Dr. Ghazi shares his journey from laparoscopic surgery in Europe to robotic surgery in the US, emphasizing the need for realistic surgical training tools. He developed 3D-printed, hydrogel organs that simulate bleeding, enhancing training realism. At Hopkins, Dr. Ghazi established SLICE (Surgical Learning and Innovation Cen...
|
- Details
- Oliver Sartor discusses his approach to treating low-volume metastatic prostate. Dr. Sartor emphasizes the importance of molecular imaging, particularly PSMA PET, to define low-volume and oligometastatic disease accurately. He advocates for a "total therapy" approach, combining androgen deprivation, novel hormones, and targeted radiation, including SBRT for metastatic sites and pelvic radiation. D...
|
- Details
- Diane Newman interviews Siobhan Sutcliffe about a project funded as part of the White House Moonshot Initiative. This project aims to gather more data to support PSA-based risk-stratified screening for prostate cancer. By using a man's PSA value, the research seeks to determine whether he might develop clinically significant prostate cancer that could potentially shorten his lifespan. The study in...
|
- Details
- Zach Klaassen discusses with Todd Morgan about innovative post-prostatectomy biomarkers. Dr. Morgan presents findings on a new AI model developed by ArteraAI for assessing biochemical recurrence in prostate cancer patients post-prostatectomy. This model, validated using clinical data and digital pathology from two significant trials, shows high predictive accuracy. It aims to distinguish patients...
|
- Details
- Rana McKay discusses her team’s study on the HSD3B1 gene and its link to prostate cancer outcomes, published in JAMA Network Open. The study focuses on the adrenal-permissive allele of HSD3B1, which influences the body's conversion of DHEA to potent androgens, affecting responses to hormonal therapy and prostate cancer progression. Dr. McKay explains that this genetic variant shows variable preval...
|
- Details
- Rashid Sayyid and Zach Klaassen explore the findings of the ProScreen trial, a rigorous examination into sequential prostate cancer screening using PSA, a kallikrein panel, and MRI. Highlighting the study's aim to refine screening methods by enhancing detection rates of high-grade cancers while reducing unnecessary diagnoses of low-grade conditions, they delve into the process and preliminary resu...
|
- Details
- Ruchika Talwar welcomes Avinash Maganty to discuss research on value-based payment models in prostate cancer management, published in Cancer Medicine. Dr. Maganty explains that following the MACRA initiative of 2017, urologists had to adapt to payment models like MIPS and accountable care organizations, which potentially influence treatment decisions, especially in discretionary cases like low-gra...
|
- Details
- Alicia Morgans and Nima Sharifi discuss the role of the HSD3B1 gene and its variants in prostate cancer. Dr. Sharifi explains that the adrenal permissive allele of HSD3B1 is common in people of European ancestry and is associated with increased conversion of adrenal androgen precursors to potent androgens like DHT. This allele is linked to faster progression and higher prostate cancer-specific mor...
|
